The Pharmaceutical drug, commonly known as Zantac was developed to help prevent and treat heartburn, gastroesophageal reflux disease, ulcers, acid reflux and sour stomach. On April 1, 2020 The United States Food and Drug Administration announced it is requesting that manufacturers withdraw all prescription and over-the-counter ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or over the counter use in the United States.
NDMA is a probable human carcinogen (a substance that could cause cancer). In the summer of 2019, the FDA became aware of independent laboratory testing that found NDMA in ranitidine. Although it is common to ingest low levels of NDMA in our diet, present in food and water, sustained higher levels of exposure may increase the risk of cancer in humans.
Low levels of NDMA are commonly ingested in the diet, for example NDMA is present in foods and in water. These low levels would not be expected to lead to an increase in the risk of cancer. However, sustained higher levels of exposure may increase the risk of cancer in humans. The FDA continued its investigation and warned the public in September 2019 of the potential risks and to consider alternative OTC and prescription treatments.
New FDA testing and evaluation prompted by information from third-party laboratories confirmed that NDMA levels increase in ranitidine even under normal storage conditions, and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers. The testing also showed that the older a ranitidine product is, or the longer the length of time since it was manufactured, the greater the level of NDMA. These conditions may raise the level of NDMA in the ranitidine product above the acceptable daily intake limit.
If you have taken Zantac for one year or greater and have developed the below diseases please give us a call so that we may evaluate your potential claim:
•Intestinal cancer (including colon or rectal cancer),
•Prostate cancer (for patients diagnosed at age 65 or younger),
•Non-Hodgkins lymphoma, or
Call Delphin Law Offices today: 337.439.3939
Attorney Mark A. Delphin
Delphin Law Offices
626 Broad Street Lake Charles, LA 70601